Homepage

Prelude Therapeutics Incorporated

PRLD NASDAQ Categories PDF
Healthcare · Biotechnology · United States · Updated May 11, 1:51pm
$4.88
Price
$272.0M
Market Cap
131
Employees
1.10
Beta
Krishna Vaddi
CEO
Business Description

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

Business History
Price Overview
Last updated: May 11, 2026 1:51pm (just now)
$4.89
+0.03 (+0.53%)
Day Range
$4.74 – $5.14
52-Week Range
$0.75 – $5.54
50-Day MA
$3.87
200-Day MA
$2.20
Volume
209,116.70
Analyst Price Targets
Low $8.00
Consensus $8.00
High $8.00
(6 analysts)
Share Structure
Outstanding 76,835,443.00
Float 40,277,818.00
Free Float 52.4%
Normal free float — 52.4% of shares trade freely, ~47.6% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
Period Revenue Net Income Net Margin YoY/QoQ
Key Metrics
API Direct from provider CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALC
Stock Price / EPS (Diluted)
-3.78
Stock Price: $4.88
EPS (Diluted): -1.29
P/B Ratio (Price vs net asset value)
API
Stock Price / Book Value Per Share
3.25
Stock Price: $4.88
Total Equity: $68.64M
Shares: 76,956,194
EV/EBITDA (Total value vs operating profit)
API
Enterprise Value / EBITDA
-2.49
Market Cap: $272.00M
Total Debt: $17.79M
Cash: $35.26M
EBITDA: -$102.86M
Enterprise Value (Takeover price (cap + debt - cash))
API
Market Cap + Total Debt - Cash
$144.4M
Market Cap: $272.00M
Total Debt: $17.79M
Cash: $35.26M
Gross Margin (Revenue left after direct costs)
API
Gross Profit / Revenue
85.9%
Gross Profit: $10.43M
Revenue: $12.14M
Operating Margin (Revenue left after all operations)
API
Operating Income / Revenue
-861.3%
Operating Income: -$104.57M
Revenue: $12.14M
Net Margin (Revenue left as actual profit)
API
Net Income / Revenue
-819.6%
Net Income: -$99.50M
Revenue: $12.14M
ROE (Profit from shareholder equity)
API
Net Income / Total Equity
-130.0%
Net Income: -$99.50M
Total Equity: $68.64M
ROIC (Profit from all invested capital)
API
NOPAT / Invested Capital
-114.8%
Operating Income: -$104.57M
Tax Rate: 0.0%
Equity: $68.64M
Total Debt: $17.79M
Cash: $35.26M
Current Ratio (Can it pay short-term bills)
API
Current Assets / Current Liabilities
1.99
Current Assets: $105.69M
Current Liabilities: $52.99M
Debt/Equity (Leverage — debt vs equity)
CALC
Total Debt / Total Equity
0.26
Short-Term Debt: $2.74M
Long-Term Debt: $15.05M
Total Debt: $17.79M
Total Equity: $68.64M
Rev/Share (Top-line per share)
CALC
Revenue / Shares Outstanding
$0.16
Revenue: $12.14M
Shares: 76,956,194
Book Value/Share (Net assets per share)
CALC
(Total Assets - Total Liabilities) / Shares
$0.89
Total Equity: $68.64M
Shares: 76,956,194
FCF/Share (Real cash generated per share)
CALC
(Operating Cash Flow + CapEx) / Shares
$-0.73
Operating CF: -$56.30M
CapEx: -$67,000
Shares: 76,956,194
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
API
Last Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $4.88
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$99.50M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares PRLD against LLM-researched typical ranges for its industry. One research call per industry, cached indefinitely — every stock in the same industry reuses the same baseline.
Deep Analysis

Pre-flight intelligence scans the company first, then routes to the right analytical methods.

0 Company Classification — What type of company is this?
1 Industry Landscape — Where is the industry headed?
2 Company Momentum — Where is this company trending?
3 Forward Projection — 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a DCF Valuation — Present value of future cash flows
4b Earnings Power Value — Floor value — worth with zero growth
4c Anchored PE — Industry PE adjusted for growth differential
4d Reverse DCF — What growth is the market pricing in?
4e Revenue-Based DCF — For growth/narrative companies (skip if mature earner)
4f Anchored P/S — Price-to-Sales peer comparison (skip if mature earner)
4g Scenario Analysis — Bull / Base / Bear (skip if mature earner)
4h Dividend Discount Model — For dividend/income stocks only
4i Book Value Analysis — For deep value / turnaround stocks only
4j Insider Activity — Are insiders buying or selling?
4f Cash Flow Quality — How trustworthy is the FCF?
4g Debt Maturity Risk — Can it handle its debt?
4h Macro Environment — Rates, market valuation, volatility
4i Sector Intelligence — How does this company compare within its sector?
4j Revenue Confidence — How reliable is the growth projection?
4k Sensitivity Analysis — How fragile is the fair value estimate?
4l Sector Demand Cycle — Is the sector in a boom, steady state, or contraction?
5 AI Investigation — Adaptive research engine (Claude)
5b Thesis Evaluation — What does the market believe? (narrative/platform stocks only)
6 Valuation Synthesis — Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Metric 2021 2022 2023 2024 2025
Revenue $0 $0 $0 $7.0M $12.1M
Cost of Revenue $0 $0 $0 $0 $1.7M
Gross Profit $0 $0 $0 $7.0M $10.4M
Operating Expenses $113.7M $123.5M $132.3M $146.7M $115.0M
Operating Income -$113.7M -$123.5M -$132.3M -$139.7M -$104.6M
Net Income -$111.7M -$115.4M -$121.8M -$127.2M -$99.5M
EBITDA -$112.8M -$122.2M -$131.1M -$137.9M -$102.9M
EPS $-2.33 $-2.27 $-2.02 $-1.68 $-1.29
EPS (Diluted) — — — — —
Balance Sheet (Annual)
Metric 2021 2022 2023 2024 2025
Cash & Equivalents $31.8M $30.6M $25.3M $12.5M $35.3M
Total Current Assets $295.1M $204.4M $235.6M $135.9M $105.7M
Total Assets $305.1M $220.5M $277.7M $175.5M $141.3M
Current Liabilities $19.2M $21.7M $21.8M $25.6M $53.0M
Long-Term Debt $0 $0 $0 $0 $15.0M
Total Liabilities $19.2M $25.1M $40.6M $44.1M $72.7M
Total Equity $285.9M $195.4M $237.1M $131.5M $68.6M
Retained Earnings -$219.1M -$334.6M -$456.4M -$583.6M -$683.1M
Cash Flow (Annual)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow -$83.5M -$83.7M -$107.1M -$102.9M -$56.3M
Capital Expenditure -$2.3M -$3.0M -$3.5M $-764,000 $-67,000
Free Cash Flow -$85.9M -$86.7M -$110.6M -$103.7M -$56.4M
Acquisitions (net) $0 $0 $0 $0 $0
Debt Repayment — — — — —
Dividends Paid — — — — —
Stock Buybacks $0 $0 $0 $0 $0
Net Change in Cash -$182.4M -$1.2M -$5.3M -$12.8M $22.0M
Analyst Estimates (Annual)
Metric 2027 2028 2029 2030
Revenue $50.0M
$50.0M – $50.0M
 $200.0M
$200.0M – $200.0M
 $100.0M
$100.0M – $100.0M
 $551.5M
$551.5M – $551.5M
EBITDA $10.0M
$10.0M – $10.0M
 $40.0M
$40.0M – $40.0M
 $20.0M
$20.0M – $20.0M
 $110.3M
$110.3M – $110.3M
Net Income -$49.3M
-$49.3M – -$49.3M
 -$49.6M
-$49.6M – -$49.6M
 -$54.6M
-$54.6M – -$54.6M
 $120.1M
$120.1M – $120.1M
EPS — — — —
Growth Trends (YoY %)
Metric 2022 2023 2024 2025
Revenue Growth — — — +73.4%
Gross Profit Growth — — — +49.0%
Operating Income Growth -8.6% -7.1% -5.6% +25.2%
Net Income Growth -3.4% -5.5% -4.4% +21.8%
EBITDA Growth -8.3% -7.3% -5.2% +25.4%
Insider Trading (Recent)
Date Insider Type Shares Price Value
2026-05-01 Morris Charles Q A-Award 450,000.00 $4.70 $2.1M
2026-04-27 RA CAPITAL MANAGEMENT, L.P. J-Other 1,407,000.00 $0.00 $141
2026-04-27 RA CAPITAL MANAGEMENT, L.P. J-Other 1,407,000.00 $0.00 $141
2026-04-21 RA CAPITAL MANAGEMENT, L.P. 0.00 $0.00 $0
2026-04-21 Bonita David P P-Purchase 1,689,189.00 $4.44 $7.5M
2026-04-21 Bonita David P P-Purchase 1,126,126.00 $4.44 $5.0M
2026-04-21 ORBIMED ADVISORS LLC P-Purchase 1,689,189.00 $4.44 $7.5M
2026-04-21 ORBIMED ADVISORS LLC P-Purchase 1,126,126.00 $4.44 $5.0M
2026-04-21 BAKER BROS. ADVISORS LP P-Purchase 2,137,651.00 $0.00 $214
2026-04-21 BAKER BROS. ADVISORS LP P-Purchase 114,601.00 $0.00 $11
2026-04-15 Morris Charles Q 0.00 $0.00 $0
2026-03-05 Brusky Sean P. 0.00 $0.00 $0
2026-03-05 Brusky Sean P. 275,000.00 $0.00 $0
2026-02-04 Combs Andrew A-Award 230,000.00 $2.30 $529,000
2026-02-04 Scherle Peggy A-Award 230,000.00 $2.30 $529,000
2026-02-04 Lim Bryant David A-Award 275,000.00 $2.30 $632,500
2026-02-04 Vaddi Krishna A-Award 837,000.00 $2.30 $1.9M
2025-11-05 Sandor Victor A-Award 121,285.00 $1.39 $168,586
2025-10-17 Dorton Katina 0.00 $0.00 $0
2025-10-04 Huang Jane M-Exempt 9,375.00 $0.00 $0
Community AI Feedback
Sign in to Contribute
No community reviews yet for PRLD. Be the first — export the analysis to your AI and contribute back.
My Notes personal — only you see this
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.193 · 1946f027 · 2026-05-08 18:57:27